Julia Hambach

Hamburg, HH 20246, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells.

CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells.

Journal: Scientific reports

Published: June 04, 2025

Imaging BiTE-Mediated Activation of Primary Human CD8+ T Cells.

Imaging BiTE-Mediated Activation of Primary Human CD8+ T Cells.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: April 12, 2025

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE-Expressing Cells.

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE-Expressing Cells.

Journal: Allergy

Published: April 04, 2025

Instructions for meaningful figures in radiological research publications.

Instructions for meaningful figures in radiological research publications.

Journal: RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin

Published: May 15, 2024

Generation and characterization of antagonistic anti-human CD39 nanobodies.

Generation and characterization of antagonistic anti-human CD39 nanobodies.

Journal: Frontiers in immunology

Published: October 26, 2023

Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire.

Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire.

Journal: Nature communications

Published: October 23, 2023

An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells.

An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells.

Journal: Kidney international

Published: October 16, 2023

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy.

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy.

Journal: Frontiers in immunology

Published: August 02, 2022

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.

Journal: Frontiers in immunology

Published: July 28, 2022

High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1.

High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 29, 2022

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells.

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells.

Journal: Frontiers in immunology

Published: December 17, 2021

Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells.

Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells.

Journal: Frontiers in immunology

Published: April 30, 2021

Showing 1-12 of 19

Last Updated: 09/26/2026